Australia markets open in 8 hours 58 minutes

EyePoint Pharmaceuticals, Inc. (EYPT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.32+0.31 (+3.87%)
As of 11:01AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 417.20M
Enterprise value 122.47M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.85
Price/book (mrq)1.67
Enterprise value/revenue 2.45
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.60
52-week change 3-7.18%
S&P500 52-week change 323.89%
52-week high 330.99
52-week low 35.67
50-day moving average 311.72
200-day moving average 316.03

Share statistics

Avg vol (3-month) 31.16M
Avg vol (10-day) 3966.96k
Shares outstanding 552.08M
Implied shares outstanding 652.08M
Float 834.26M
% held by insiders 11.41%
% held by institutions 1110.96%
Shares short (14 June 2024) 48.98M
Short ratio (14 June 2024) 49.45
Short % of float (14 June 2024) 420.32%
Short % of shares outstanding (14 June 2024) 417.25%
Shares short (prior month 15 May 2024) 48.13M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 309 Dec 2020
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 309 Dec 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -157.77%
Operating margin (ttm)-285.19%

Management effectiveness

Return on assets (ttm)-22.12%
Return on equity (ttm)-48.07%

Income statement

Revenue (ttm)50.02M
Revenue per share (ttm)1.17
Quarterly revenue growth (yoy)52.10%
Gross profit (ttm)N/A
EBITDA -84.97M
Net income avi to common (ttm)-78.92M
Diluted EPS (ttm)-1.81
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)299.35M
Total cash per share (mrq)5.75
Total debt (mrq)5.72M
Total debt/equity (mrq)2.29%
Current ratio (mrq)5.08
Book value per share (mrq)5.01

Cash flow statement

Operating cash flow (ttm)-12.46M
Levered free cash flow (ttm)9.88M